MNMasato Nakaguro

Masato Nakaguro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Masato Nakaguro has a total of 418 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A clinicopathological and molecular analysis of intrasalivary thymic-like neoplasms—An unestablished salivary gland tumor entity

    by Mei Hamada, Yu Miyama, Masato Nakaguro, Yukako Shintani-Domoto, Kai Miyazaki, Kohei Nakamura, Tomoko Uchiyama, Yuya Murata, Kaori Takamura, Haruka Hatakeyama, et al.

    Salivary gland tumors with thymic-like differentiation have recently been recognized as a distinct pathological entity, although their origin is unknown and their defining features remain incompletely characterized. These lesions encompass carcinoma showing thymus-like elements/differentiation, as well as thymus-like lesions, whose malignant potential remains uncertain. In this study, we collected 9 cases of salivary gland tumors with thymic-like differentiation and investigated their clinicopathological, immunohistochemical, and molecular characteristics. Thymic-like differentiation was defined as tumor cell proliferation with nested, trabecular, and solid architecture, the presence of abundant lymphocytic infiltrates, and the expression of CD5 and CD117/c-KIT. All tumors arose in the parotid gland, and the median age of the patients was 63 years. Histologically, 8 tumors were frankly malignant with marked nuclear atypia, among which benign components were observed in 3 cases. One case consisted solely of a benign component. Although Hassall’s corpuscle-like structures were noted in 2 cases, no definitive thymic remnants were identified in any of the cases. Amyloid deposition containing CK19 and CK5 as its components was observed in 3 cases. Targeted DNA sequencing revealed alterations primarily in tumor suppressor genes including PTEN, RB1, and TP53 in the malignant components, but no variants were detected in the benign components. These tumors comprise both malignant carcinomatous and benign components. We propose designating these tumors collectively as “intrasalivary thymic-like neoplasms.”


  • Open Access

    Pleomorphic Adenoma of the Palate with Bizarre Ductal and Myoepithelial Cells: A Case Image

    by Katsutoshi Hirose, Masato Nakaguro, Kohei Kawamura, Taisuke Mori, Satoru Toyosawa

  • Open Access

    Association of Epstein-Barr virus genomic alterations with human pathologies

    by Htet Thiri Khine, Yoshitaka Sato, Motoharu Hamada, Miki Umeda, Akira Iizuka, Shika Son, Haruto Arai, Yuki Kojima, Takahiro Watanabe, Azumi Naruse, et al.

    Epstein-Barr virus (EBV) infects >90% of humans and is associated with both hematological and epithelial malignancies. Here, we analyzed 990 EBV genomes (319 newly sequenced and 671 from public databases) from patients with various diseases to comprehensively characterize genomic variations, including single nucleotide variations (SNVs) and structural variations (SVs). Although most SNVs were a result of conservative evolution and reflected the geographical origins of the viral genomes, we identified several convergent SNV hot spots within the central homology domain of EBNA3B, the transactivation domain of EBNA2, and the second transmembrane domain of LMP1. These convergent SNVs seem to fine-tune viral protein functionality and immunogenicity. SVs, particularly large deletions, were frequently observed in chronic active EBV disease (28%), EBV-positive diffuse large B-cell lymphoma (48%), extranodal natural killer/T-cell lymphoma (41%), and Burkitt lymphoma (25%), but were less common in infectious mononucleosis (11%), posttransplant lymphoproliferative disorder (7%), and epithelial malignancies (5%). In hematological malignancies, deletions often targeted viral microRNA clusters, potentially promoting viral reactivation and lymphomagenesis. Nondeletion SVs, such as inversions, were also prevalent, with several inversions disrupting the C promoter to suppress latent gene expression, thereby maintaining viral dormancy. Furthermore, recurrent EBNA3B deletions suggested that this viral transcription factor functions as a tumor suppressor. EBNA3B knockout experiments in vitro revealed downregulation of human tumor suppressors, including PTEN and RB1, which could explain the enhanced lymphomagenesis observed in EBNA3B-deficient lymphoblastoid cell line xenografts. Our findings highlight both disease-specific and general contributions of EBV genomic alterations to human cancers, particularly in hematological malignancies.


  • Open Access

    Correlation between basal cell adenoma and basal cell adenocarcinoma of the salivary gland: a histomorphological and molecular review of 129 cases

    by Haruna Yagi, Yoshitaka Utsumi, Yuichiro Tada, Satoshi Baba, Toshihide Iwashita, Kennosuke Karube, Makoto Urano, Toshitaka Nagao, Masato Nakaguro

    Basal cell adenoma (BCA) and basal cell adenocarcinoma (BCAC) are salivary gland tumors with biphasic differentiation, composed of luminal ductal cells and abluminal basal cells with a high nuclear-to-cytoplasmic ratio. While BCA is a relatively common benign tumor, BCAC is a rare malignancy, and its genetic context and relationship with BCA remain unclear. We investigated 93 BCA and 36 BCAC cases to further characterize these two tumor entities from histological and molecular perspectives. BCA/BCAC proliferated in a mixture of tubular, trabecular, solid, cribriform, and membranous patterns. A jigsaw puzzle pattern, peripheral palisading, S100-positive stroma, cystic change, and sclerosis were observed in approximately 50% of the cases. BCAC demonstrated the following malignant features: infiltration to surrounding tissue, tumor necrosis, and increased mitotic activity (81%, 22%, and 22%, respectively). The nuclear expression of β-catenin was frequently observed in both BCA and BCAC (89% and 60%), and CTNNB1 hotspot mutations were detected in 46% and 48% of BCA and BCAC cases, respectively. Tubular patterns of growth, jigsaw puzzle patterns, peripheral palisading, S100-positive stroma, and cystic changes were more common in β-catenin-positive BCA/BCAC than in β-catenin-negative BCA/BCAC. Among the β-catenin-negative BCA/BCAC cases, one case each harbored PLAG1 and MYB rearrangements. We concluded that β-catenin-positive BCA and BCAC share common histologic and molecular features, and BCAC is considered a malignant counterpart of BCA. β-Catenin-negative BCA/BCAC might include morphological mimickers, which can be genetically classified into other tumor types, including pleomorphic adenoma and adenoid cystic carcinoma.


  • The clinicopathological and prognostic significance of autonomic nerves in salivary duct carcinoma

    by Manami Kajiwara, Hideaki Takahashi, Masato Nakaguro, Daisuke Kawakita, Hideaki Hirai, Yoshitaka Utsumi, Makoto Urano, Yukiko Sato, Kiyoaki Tsukahara, Satoshi Kano, et al.

    Many researchers have focused on the role of the autonomic nervous system in the tumor microenvironment. Autonomic nerves include the sympathetic and parasympathetic nerves, which are known to induce cancer growth and metastasis. However, in salivary duct carcinoma (SDC), a rare and highly malignant tumor, the issue should be investigated from both biological and therapeutic perspectives. We explored the clinicopathological and prognostic implications of the autonomic nerves in 129 SDCs. Immunohistochemistry was performed to determine the nature of each nerve using antibodies against S100, tyrosine hydroxylase (TH) as a sympathetic marker, and vesicular acetylcholine transporter (VAChT) as a parasympathetic marker. The area of each marker-positive nerve was digitized and evaluated quantitatively. Double immunofluorescence for TH and VAChT was performed in selected cases. The expression of the secreted neurotrophins was also examined. S100-positive nerves were present in the cancer tissue in 94 of 129 cases (72.9%). Among them, TH-positive sympathetic nerves and/or VAChT-positive parasympathetic nerves were identified in 92 cases (97.9%), and 59 cases (62.8%) had TH/VAChT-co-expressing nerves. Double immunofluorescence revealed a mosaic pattern of sympathetic and parasympathetic fibers in co-expressing nerve bundles. The presence of autonomic nerves, regardless of their area, was significantly associated with aggressive histological features, advanced T/N classification, and a poor prognosis, with shorter disease-free and overall survival. There was an association between some tumor immune microenvironment-related markers and the autonomic nerve status, but not the latter and the secreted neurotrophin expression. This study suggests that autonomic nerves might play a role in the progression of SDC.


  • Prognostic value and clinicopathological roles of the tumor immune microenvironment in salivary duct carcinoma

    by Hideaki Hirai, Masato Nakaguro, Yuichiro Tada, Natsuki Saigusa, Daisuke Kawakita, Yoshitaka Honma, Satoshi Kano, Kiyoaki Tsukahara, Hiroyuki Ozawa, Takuro Okada, et al.

    Salivary duct carcinoma (SDC) is an aggressive type of salivary gland carcinoma. Recently, immunotherapies targeting immune checkpoints, including PD1, PD-L1, CTLA4, and LAG3, have had a considerable prognostic impact on various malignant tumors. The implementation of such immune checkpoint inhibitor (ICI) therapies has also been attempted in cases of salivary gland carcinoma. The tumor immune microenvironment (TIME) is implicated in tumorigenesis and tumor progression and is closely associated with the response to ICI therapies. However, the TIME in SDC has not been fully explored. We examined the immunohistochemical expression of CD8, FOXP3, PD1, PD-L1, CTLA4, LAG3, and mismatch repair (MMR) proteins, tumor-infiltrating lymphocytes (TILs), and microsatellite instability (MSI) status in 175 cases of SDC. The associations between these TIME-related markers and the clinicopathological factors and prognosis were evaluated. An elevated expression of CD8, FOXP3, PD1, CTLA4, and LAG3 was associated with more aggressive histological features and an advanced N and/or M classification, elevated Ki-67 index, and poor prognosis. Furthermore, cases with a high PD-L1 expression exhibited more aggressive histological features and adverse clinical outcomes than those with a low expression. Alternatively, there was no significant correlation between TILs and clinicopathological factors. No SDC cases with an MSI-high status or MMR deficiency were found. The coexistence of both an immunostimulatory and immunosuppressive TIME in aggressive SDC might play a role in the presence of T-cell exhaustion. The contribution of multiple immune escape pathways, including regulatory T cells and immune checkpoints, may provide a rationale for ICI therapy, including combined PD1/CTLA4 blockade therapy.


  • Adenocarcinoma arising in branchioma with a KRAS and TP53 mutation

    by Natsuki Taniguchi, Akira Satou, Takanori Ito, Masato Nakaguro, Toyonori Tsuzuki

    Branchioma is a rare benign neoplasm occurring in the lower neck. Occurrence of malignant neoplasms arising in branchioma is extremely rare. Here, we report a case of adenocarcinoma arising in branchioma. A 62‐year‐old man had a right supraclavicular mass measuring 7.5 cm in diameter. The tumor contained an adenocarcinoma component encapsulated in a benign branchioma component. The adenocarcinoma component consisted of high‐ and low‐grade components, with the former accounting for 80% of the adenocarcinoma. The high‐grade component was immunohistochemically characterized by diffuse strong p53 expression, while the low‐grade component and branchioma component were negative for p53. Targeted sequencing analysis for the branchioma and adenocarcinoma components revealed that the adenocarcinoma component harbored pathogenic mutations in KRAS and TP53. No definitive oncogenic drivers were detected in the branchioma component. Based on these immunohistochemical and molecular findings, we suggest that the KRAS mutation contributed to the pathogenesis of the adenocarcinoma, and the TP53 mutation played a key role in the transition from low‐grade to high‐grade adenocarcinoma.